Impact of decreasing copayments on medication adherence within a disease management environment.
This paper estimates the effects of a large employer's value-based insurance initiative designed to improve adherence to recommended treatment regimens. The intervention reduced copayments for five chronic medication classes in the context of a disease management (DM) program. Compared to a control employer that used the same DM program, adherence to medications in the value-based intervention increased for four of five medication classes, reducing nonadherence by 7-14 percent. The results demonstrate the potential for copayment reductions for highly valued services to increase medication adherence above the effects of existing DM programs.
Chernew
Michael E
ME
Harvard Medical School, Boston, Massachusetts, USA. chernew@hcp.med.harvard.edu
Shah
Mayur R
MR
Wegh
Arnold
A
Rosenberg
Stephen N
SN
Juster
Iver A
IA
Rosen
Allison B
AB
Sokol
Michael C
MC
Yu-Isenberg
Kristina
K
Fendrick
A Mark
AM
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use; D015331:Cohort Studies; D017047:Cost Sharing; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D019468:Disease Management; D005260:Female; D006264:Health Benefit Plans, Employee / Q000191:economics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D014481:United States
D000924:Anticholesteremic Agents